These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34888361)

  • 1. Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination.
    Porcari A; Bussani R; Merlo M; Varrà GG; Pagura L; Rozze D; Sinagra G
    Front Cardiovasc Med; 2021; 8():749523. PubMed ID: 34888361
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
    Papathanasiou M; Jakstaite AM; Oubari S; Siebermair J; Wakili R; Hoffmann J; Carpinteiro A; Hagenacker T; Thimm A; Rischpler C; Kessler L; Rassaf T; Luedike P
    ESC Heart Fail; 2022 Jun; 9(3):1740-1748. PubMed ID: 35178887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left atrial strain imaging differentiates cardiac amyloidosis and hypertensive heart disease.
    Rausch K; Scalia GM; Sato K; Edwards N; Lam AK; Platts DG; Chan J
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):81-90. PubMed ID: 32728989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.
    Cipriani A; De Michieli L; Porcari A; Licchelli L; Sinigiani G; Tini G; Zampieri M; Sessarego E; Argirò A; Fumagalli C; De Gaspari M; Licordari R; Russo D; Di Bella G; Perfetto F; Autore C; Musumeci B; Canepa M; Merlo M; Sinagra G; Gregori D; Iliceto S; Perazzolo Marra M; Cappelli F; Rapezzi C
    JACC CardioOncol; 2022 Nov; 4(4):458-470. PubMed ID: 36444225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.
    Debonnaire P; Claeys M; De Smet M; Trenson S; Lycke M; Demeester C; Van Droogenbroeck J; De Vriese AS; Verhoeven K; Vantomme N; Van Meirhaeghe J; Willandt B; Lambert M; de Paepe P; Delanote J; De Geeter F; Tavernier R
    Acta Cardiol; 2022 Nov; 77(9):791-804. PubMed ID: 34565298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis.
    Aimo A; Fabiani I; Giannoni A; Mandoli GE; Pastore MC; Vergaro G; Spini V; Chubuchny V; Pasanisi EM; Petersen C; Poggianti E; Taddei C; Castiglione V; Latrofa S; Panichella G; Sciaccaluga C; Georgiopoulos G; Passino C; Cameli M; Emdin M
    Eur Heart J Cardiovasc Imaging; 2022 Dec; 24(1):130-141. PubMed ID: 35292807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients.
    Versteylen MO; Brons M; Teske AJ; Oerlemans MIFJ
    Biomedicines; 2022 Jul; 10(8):. PubMed ID: 35892668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prevalence of Advanced Interatrial Block and Its Relationship to Left Atrial Function in Patients with Transthyretin Cardiac Amyloidosis.
    Lindow T; Lindqvist P
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34201866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chest pain in cardiac amyloidosis: occurrence, causes and prognostic significance.
    De Michieli L; De Gaspari M; Sinigiani G; Lupi A; Vedovelli L; Salvalaggio A; Della Barbera M; Rizzo S; Pilichou K; Cecchin D; Briani C; Gregori D; Tarantini G; Berno T; Trentin L; Basso C; Corrado D; Iliceto S; Perazzolo Marra M; Cipriani A
    Int J Cardiol; 2023 Oct; 389():131204. PubMed ID: 37481000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
    Aimo A; Merlo M; Porcari A; Georgiopoulos G; Pagura L; Vergaro G; Sinagra G; Emdin M; Rapezzi C
    Eur J Heart Fail; 2022 Dec; 24(12):2342-2351. PubMed ID: 35509173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heart damage in the combined types of systemic amyloidosis].
    Rybakova MG; Vlasova MT; Kuznetsova IA; Krylova YS
    Arkh Patol; 2021; 83(5):21-26. PubMed ID: 34609800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.
    Sanchis K; Cariou E; Colombat M; Ribes D; Huart A; Cintas P; Fournier P; Rollin A; Carrié D; Galinier M; Maury P; Duparc A; Lairez O;
    Amyloid; 2019 Sep; 26(3):128-138. PubMed ID: 31172799
    [No Abstract]   [Full Text] [Related]  

  • 13. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
    Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
    JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction.
    Goland S; Volodarsky I; Fabricant Y; Livschitz S; Tshori S; Cuciuc V; Zilberman L; Fugenfirov I; Meledin V; Shimoni S; Josfberg S; George J
    PLoS One; 2021; 16(7):e0254104. PubMed ID: 34242301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Occult Transthyretin Amyloidosis in Patients with Severe Aortic Stenosis and Amyloid Red Flags.
    Jakstaite AM; Vogel JK; Luedike P; Jánosi RA; Carpinteiro A; Rischpler C; Herrmann K; Rassaf T; Papathanasiou M
    J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Right Atrial Impairment and Association with Outcomes in Cardiac Amyloidosis.
    Singulane CC; Slivnick JA; Addetia K; Asch FM; Sarswat N; Soulat-Dufour L; Mor-Avi V; Lang RM
    J Am Soc Echocardiogr; 2022 Aug; 35(8):829-835.e1. PubMed ID: 35398489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
    Porcari A; Rossi M; Cappelli F; Canepa M; Musumeci B; Cipriani A; Tini G; Barbati G; Varrà GG; Morelli C; Fumagalli C; Zampieri M; Argirò A; Vianello PF; Sessarego E; Russo D; Sinigiani G; De Michieli L; Di Bella G; Autore C; Perfetto F; Rapezzi C; Sinagra G; Merlo M
    Eur J Heart Fail; 2022 Jul; 24(7):1227-1236. PubMed ID: 35509181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy.
    Melero Polo J; Roteta Unceta-Barrenechea A; Revilla Martí P; Pérez-Palacios R; Gracia Gutiérrez A; Bueno Juana E; Andrés Gracia A; Atienza Ayala S; Aibar Arregui MÁ
    Cardiol J; 2023; 30(2):266-275. PubMed ID: 34355777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies.
    Donnellan E; Wazni OM; Hanna M; Elshazly MB; Puri R; Saliba W; Kanj M; Vakamudi S; Patel DR; Baranowski B; Cantillon D; Dresing T; Jaber WA
    JACC Clin Electrophysiol; 2020 Sep; 6(9):1118-1127. PubMed ID: 32972546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.